Isodiol International Inc. (CSE:ISOL)(OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator and market leader, is pleased to announce the launch of its automated retail strategy, with the Company planning to roll out a nation-wide network of branded kiosks, which will provide consumers with convenient access to natural health and wellness cannabinoid (CBD) based products.

The initial roll-out of Isodiol’s kiosks will focus on the launch of its Iso-Sport branded products, as well as the recently launched Kathy Ireland Health & Wellness brand. As such, the Company will support its nationwide rollout through close marketing collaboration with its brand influencers to inspire, educate and connect directly with customers. The curated user interface and integrated digital signage will also ensure that the product and brand presentations remain consistent.


“Companies with early insights into new trends and norms of daily commercial behavior are poised to prosper,” said CEO of Isodiol, Marcos Agramont. “As it stands, there is a global trend and substantial increase in the deployment of interactive self-service kiosks around the world.”

The Company plans to introduce its kiosks at various high profile and high traffic locations, as well as co-locating within retailers such as pharmacies, convenient stores, wellness centers, gyms, and more. The products and locations of these units will comply with the appropriate legislation in each jurisdiction. The use of such systems will also include innovative ways to collect data on inventory and customer behavior and preferences, thus allowing better recommendations to be offered based on purchase trends, or other metrics such as a user’s input of specific health conditions.

The kiosks will have different recognition capabilities in order to verify users, as well as provide many different payment options including credit cards, debit cards, PayPal, Google Wallet, and Apple Pay. Additionally, the Company expects cryptocurrency, such as Bitcoin to be an accepted payment method in the near future.

A mobile application will also provide consumers with the ability to browse products remotely and determine in real time where to find a kiosk stocked with their desired products. The company will also seek to further harness the power of social media, integrated marketing campaigns, promos, coupons and more. For instance,  the Company’s automated retail system will allow customer interaction  with the ability to tweet messages directly to the kiosks, and also the ability to upload pictures to Instagram for samples or discounts.

Further, through its enterprise scale cloud based platform, the Company will be able to centrally monitor its network of automated retail units, and manage and optimize in real-time every aspect of its operations, from merchandising to remote technical support.

“In an era of growing mobility, consumers demand for easy access to products and services anytime and from anywhere,” added Agramont. “We are excited to begin a new phase of our retail strategy and significantly increase our footprint and direct  access to consumers  for our industry leading line of CBD products.”

The Company is also pleased to announce that it debuted its Iso-Sport vending machine at the Phoenix Europa Games, which took place August 11-12, 2018. As regulation continues to become favorable, the Company intends to place multiple vending machines in gyms and fitness centers across the globe. The Company believes this is another innovative measure to provide consumers with convenient access to natural health and wellness CBD based products around the globe.

For further information, please visit http://www.azfamily.com/story/38864802/vendor-discusses-athletes-using-cannabis-at-europa-games

For more information on Isodiol, please visit www.isodiol.com

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade pure, natural CBD and the industry leader in the manufacturing and development of CBD consumer products.

Isodiol is the pioneer of many firsts in the CBD industry, including the commercialization of 99%+ pure, natural isolated CBD, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.

Join Us On Facebook: https://www.facebook.com/IsodiolInternationalInc/
Twitter: @Isodiolintlinc

ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director

INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Click here to connect with Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) for an Investor Presentation 

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less